Stock Research for OMER

OMER

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

OMER Stock Chart & Research Data

The OMER chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the OMER chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


OMER Due diligence Resources & Stock Charts

The OMER stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View OMER Detailed Price Forecast - CNN Money CNN View OMER Detailed Summary - Google Finance
Yahoo View OMER Detailed Summary - Yahoo! Finance Zacks View OMER Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View OMER Trends & Analysis - Trade-Ideas Barrons View OMER Major Holders - Barrons
NASDAQ View OMER Call Transcripts - NASDAQ Seeking View OMER Breaking News & Analysis - Seeking Alpha
Spotlight View OMER Annual Report - CompanySpotlight.com OTC Report View OMER OTC Short Report - OTCShortReport.com
TradeKing View OMER Fundamentals - TradeKing Charts View OMER SEC Filings - Bar Chart
WSJ View Historical Prices for OMER - The WSJ Morningstar View Performance/Total Return for OMER - Morningstar
MarketWatch View the Analyst Estimates for OMER - MarketWatch CNBC View the Earnings History for OMER - CNBC
StockMarketWatch View the OMER Earnings - StockMarketWatch MacroAxis View OMER Buy or Sell Recommendations - MacroAxis
Bullish View the OMER Bullish Patterns - American Bulls Short Pains View OMER Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View OMER Stock Mentions - StockTwits PennyStocks View OMER Stock Mentions - PennyStockTweets
Twitter View OMER Stock Mentions - Twitter Invest Hub View OMER Investment Forum News - Investor Hub
Yahoo View OMER Stock Mentions - Yahoo! Message Board Seeking Alpha View OMER Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for OMER - SECform4.com Insider Cow View Insider Transactions for OMER - Insider Cow
CNBC View OMER Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for OMER - OTC Markets
Yahoo View Insider Transactions for OMER - Yahoo! Finance NASDAQ View Institutional Holdings for OMER - NASDAQ


Stock Charts

FinViz View OMER Stock Insight & Charts - FinViz.com StockCharts View OMER Investment Charts - StockCharts.com
BarChart View OMER Stock Overview & Charts - BarChart Trading View View OMER User Generated Charts - Trading View




Latest Financial News for OMER


Omeros Announces Research Collaboration with University of Cambridge
Posted on Tuesday December 11, 2018

Omeros Corporation (OMER) today announced that it has entered into a research collaboration with the University of Cambridge, establishing the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). The OC3IR currently is focusing on research related to OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the complement system’s lectin pathway, and to OMS906, Omeros’ lead human monoclonal antibody targeting MASP-3, the key activator of the complement system’s alternative pathway.


Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)
Posted on Thursday December 06, 2018

– EMA Confirmed OMS721 Eligibility for European Centralized Marketing Authorization Application Review –


Omeros Announces Additions to Senior Management Team
Posted on Monday December 03, 2018

Omeros Corporation (OMER) today announced that it hired two new senior management team members – Daniel Kirby as vice president and head of commercial and Justin McCue, Ph.D. as vice president of chemistry, manufacturing and controls (CMC). OMIDRIA is the company’s marketed drug and the only product of its kind for cataract and lens replacement surgery.


Edited Transcript of OMER earnings conference call or presentation 9-Nov-18 1:30pm GMT
Posted on Monday December 03, 2018

Q3 2018 Omeros Corp Earnings Call


Stock Market & Investing Books

Enter a stock symbol to view the stock details.